Genotoxicity Assessment for Patients Undergoing Radiation Treatment

This study is currently recruiting participants.
Verified December 2012 by University of Rochester
Sponsor:
Information provided by (Responsible Party):
Yuhchyau Chen, University of Rochester
ClinicalTrials.gov Identifier:
NCT00167427
First received: September 9, 2005
Last updated: December 10, 2012
Last verified: December 2012

September 9, 2005
December 10, 2012
April 2006
October 2015   (final data collection date for primary outcome measure)
Measure the Change in MN-RET in the blood [ Time Frame: Baseline and 1 day ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00167427 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Genotoxicity Assessment for Patients Undergoing Radiation Treatment
Genotoxicity Assessment for Patients Receiving Large Field Irradiation

The purpose of the research study is to evaluate an automated, laser-based technique for measuring DNA damage caused by radiation during cancer treatment in immature red blood cells.

Correlative studies: analysis of RT effect on genotoxicity by assessing cytogenetic changes (dicentrics), micronucleated lymphocytes (MN-lymph), and micronucleated reticulocytes (MN-RET) using peripheral blood of patients receiving radiation.

i) document the kinetics by which radiation-induced MN-RET enter the peripheral blood stream.

ii) benchmark the MN-RET endpoint against current gold-standard biodosimetry endpoints—dicentrics and MN-lymphocytes.

iii) measure inter-individual variation in baseline and radiation-induced MN-RET frequencies.

iv) in collaboration with several FCM-equipped laboratories, evaluate the transferability of the human MN-RET scoring assay.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patients that are scheduled to begin radiotherapy to the large-field chest region

Neoplasms
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
120
October 2018
October 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients that are scheduled to begin radiotherapy to the large-field chest region are eligible if:

    • Daily radiation dose is between 1.8 and 5 Gy/day
    • Any single dimension of field size is ≥ 15 cm
    • Provision of written informed consent

or

  • Or patients receiving IMRT or Tomotherapy, when low-dose radiation is spread out to the normal tissues, irrespective of daily radiation doses.
  • Or patients receiving radionucleotides as part of the medical treatment (cancer or non-malignant conditions)
  • Or patients who will receive diagnostic CT scans, PET/CT scans, mammograms, or diagnostic imaging requiring radionucleotides
Both
18 Years and older
No
Contact: Therese Smudzin, BS 585-275-7848 therese_smudzin@urmc.rochester.edu
Contact: Yuhchyau Chen, MD, Ph.D 585-275-5623 yuhchyau_chen@urmc.rochester.edu
United States
 
NCT00167427
URCC 3705, 1 U19 AI067733-01
No
Yuhchyau Chen, University of Rochester
Yuhchyau Chen
Not Provided
Principal Investigator: Yuhchyau Chen, MD, Ph.D Universtiy of Rochester, Dept of Radiation Oncology
University of Rochester
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP